Allstate Corp Grows Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Allstate Corp more than doubled its stake in Edwards Lifesciences during the fourth quarter, increasing holdings by 106.7% to 43,601 shares valued at about $3.7 million.
• Wall Street remains generally bullish on EW, with analysts assigning a consensus rating of Moderate Buy and an average price target of $95.65.
• Edwards Lifesciences reported solid quarterly results, beating estimates with $0.78 EPS and $1.65 billion in revenue, while insiders have sold shares in recent months.

Allstate Corp boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 106.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,601 shares of the medical research company's stock after purchasing an additional 22,511 shares during the quarter. Allstate Corp's holdings in Edwards Lifesciences were worth $3,717,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Brighton Jones LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at $266,000. NewEdge Advisors LLC increased its position in Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock valued at $2,787,000 after acquiring an additional 2,665 shares during the last quarter. Sei Investments Co. increased its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock valued at $32,285,000 after acquiring an additional 58,988 shares during the last quarter. Squarepoint Ops LLC increased its position in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock valued at $5,417,000 after acquiring an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its position in Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock valued at $21,028,000 after acquiring an additional 1,065 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on EW shares. Barclays reiterated an "overweight" rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Piper Sandler reiterated an "overweight" rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an "overweight" rating in a research report on Wednesday, February 11th. The Goldman Sachs Group reiterated a "buy" rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Finally, Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a "hold" rating in a research report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $95.65.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company's stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company's stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 105,829 shares of company stock valued at $8,799,770. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 1.1%

Shares of Edwards Lifesciences stock opened at $86.55 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $88.28. The firm's 50-day moving average is $81.62 and its two-hundred day moving average is $82.97. The stock has a market cap of $49.83 billion, a price-to-earnings ratio of 46.04, a PEG ratio of 2.19 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm's quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.